ADMA BIOLOGICS, INC. (ADMA) Current Ratio
- Current ratio · latest quarter: Value 6.97×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 6.97× | Current assets / current liabilities. $528.20M ÷ $75.76M ≈ 6.97× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 528.20M USD | Assets, Current |
| Current obligations | 75.76M USD | Liabilities, Current |
| Cash and equivalents | 136.02M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 138.23M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 239.31M USD | Inventory, Net |
| Payables | 31.72M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 3.75M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $528.20M | $75.76M | $136.02M | (m) | $138.23M | $239.31M | $31.72M | $3.75M | 6.97× |
| 2026-03-31 | $511.17M | $73.54M | $138.15M | (m) | $135.86M | $222.10M | $20.52M | $3.28M | 6.95× |
| 2025-12-31 | $466.51M | $69.54M | $87.63M | (m) | $158.43M | $206.47M | $22.52M | $2.81M | 6.71× |
| 2025-09-30 | $402.65M | $56.49M | $61.38M | (m) | $137.67M | $196.67M | $24.02M | $2.34M | 7.13× |
| 2025-06-30 | $399.56M | $74.94M | $90.28M | (m) | $109.73M | $191.46M | $29.77M | (m) | 5.33× |
| 2025-03-31 | $351.81M | $53.50M | $71.63M | (m) | $99.41M | $172.19M | $20.61M | (m) | 6.58× |
| 2024-12-31 | $331.41M | $55.54M | $103.15M | (m) | $50.00M | $170.24M | $20.22M | $0.00 | 5.97× |
| 2024-09-30 | $318.19M | $44.89M | $86.71M | (m) | $50.14M | $171.80M | $16.02M | (m) | 7.09× |
| 2024-06-30 | $303.69M | $44.18M | $88.24M | (m) | $30.11M | $179.81M | $14.18M | (m) | 6.87× |
| 2024-03-31 | $276.42M | $53.09M | $45.33M | (m) | $49.62M | $177.73M | $17.19M | (m) | 5.21× |
| 2023-12-31 | $257.01M | $49.81M | $51.35M | (m) | $27.42M | $172.91M | $15.66M | (m) | 5.16× |
| 2023-09-30 | $273.70M | $41.84M | $74.16M | (m) | $31.32M | $163.12M | $10.85M | (m) | 6.54× |
| 2023-06-30 | $266.24M | $41.95M | $62.51M | (m) | $36.73M | $161.78M | $12.08M | (m) | 6.35× |
| 2023-03-31 | $264.09M | $36.73M | $69.20M | (m) | $26.52M | $163.98M | $12.96M | (m) | 7.19× |
| 2022-12-31 | $270.40M | $39.27M | $86.52M | (m) | $15.51M | $163.28M | $13.23M | (m) | 6.89× |
| 2022-09-30 | $224.09M | $44.44M | $34.91M | (m) | $20.90M | $162.91M | $25.20M | (m) | 5.04× |
| 2022-06-30 | $222.77M | $28.07M | $52.42M | (m) | $18.88M | $146.08M | $11.39M | (m) | 7.94× |
| 2022-03-31 | $239.80M | $31.57M | $69.50M | (m) | $25.63M | $139.15M | $14.12M | (m) | 7.60× |
| 2021-12-31 | $208.73M | $30.38M | $51.09M | (m) | $28.58M | $124.72M | $12.43M | (m) | 6.87× |
| 2021-09-30 | $174.79M | $32.34M | $34.41M | (m) | $20.39M | $114.12M | $17.28M | (m) | 5.41× |
| 2021-06-30 | $171.36M | $18.19M | $42.41M | (m) | $23.54M | $99.70M | $6.17M | (m) | 9.42× |
| 2021-03-31 | $177.28M | $21.21M | $61.97M | (m) | $15.36M | $94.15M | $12.15M | (m) | 8.36× |
| 2020-12-31 | $153.74M | $19.95M | $55.92M | (m) | $13.24M | $81.54M | $11.07M | (m) | 7.71× |
| 2020-09-30 | $139.55M | $16.47M | $59.68M | (m) | $6.33M | $69.75M | $7.98M | (m) | 8.47× |
| 2020-06-30 | $142.99M | $12.88M | $75.78M | (m) | $6.51M | $56.00M | $6.91M | (m) | 11.10× |
| 2020-03-31 | $165.49M | $13.91M | $101.24M | (m) | $7.11M | $52.29M | $9.15M | (m) | 11.90× |
| 2019-12-31 | $85.82M | $14.03M | $26.75M | (m) | $3.47M | $53.06M | $9.17M | (m) | 6.12× |
| 2019-09-30 | $97.32M | $15.15M | $48.01M | (m) | $7.32M | $40.29M | $8.96M | (m) | 6.42× |
| 2019-06-30 | $103.89M | $10.13M | $73.62M | (m) | $5.09M | $23.59M | $6.79M | (m) | 10.26× |
| 2019-03-31 | $38.33M | $8.34M | $16.53M | (m) | $1.31M | $18.44M | $5.48M | (m) | 4.60× |
| 2018-12-31 | $44.53M | $9.63M | $22.75M | (m) | $1.39M | $18.62M | $5.90M | (m) | 4.63× |
| 2018-09-30 | $62.50M | $9.89M | $42.37M | (m) | $4.13M | $13.88M | $5.27M | (m) | 6.32× |
| 2018-06-30 | $73.63M | $6.92M | $55.15M | (m) | $3.80M | $12.25M | $3.10M | (m) | 10.64× |
| 2018-03-31 | $46.42M | $9.44M | $26.12M | (m) | $3.66M | $12.44M | $5.72M | (m) | 4.92× |
| 2017-12-31 | $62.34M | $9.44M | $43.11M | (m) | $3.88M | $12.63M | $5.92M | (m) | 6.60× |
| 2017-09-30 | $31.44M | $13.34M | $13.60M | (m) | $1.50M | $13.42M | $9.16M | (m) | 2.36× |
| 2017-06-30 | $44.27M | $15.65M | $25.57M | (m) | $2.29M | $13.15M | $4.67M | (m) | 2.83× |
| 2017-03-31 | $15.68M | $12.96M | $8.54M | (m) | $839.94K | $5.31M | $3.90M | (m) | 1.21× |
| 2016-12-31 | $21.66M | $11.22M | $9.91M | (m) | $1.02M | $5.02M | $2.56M | (m) | 1.93× |
| 2016-09-30 | $25.36M | $9.21M | $7.91M | (m) | $1.33M | $4.62M | $2.78M | (m) | 2.75× |
| 2016-06-30 | $29.49M | $5.08M | $12.55M | (m) | $826.72K | $4.21M | $3.32M | (m) | 5.80× |
| 2016-03-31 | $17.36M | $4.29M | $8.93M | (m) | $943.95K | $4.05M | $2.47M | (m) | 4.05× |
| 2015-12-31 | $21.29M | $4.22M | $10.44M | (m) | $924.47K | $3.45M | $2.09M | (m) | 5.05× |
| 2015-09-30 | $25.24M | $4.30M | $9.18M | (m) | $1.20M | $2.83M | $2.18M | (m) | 5.87× |
| 2015-06-30 | $27.13M | $3.20M | $7.82M | (m) | $522.50K | $2.45M | $1.65M | (m) | 8.48× |
| 2015-03-31 | $30.98M | $3.79M | $16.56M | (m) | $351.44K | $1.94M | $1.78M | (m) | 8.18× |
| 2014-12-31 | $24.09M | $4.20M | $17.20M | (m) | $383.96K | $1.71M | $1.78M | (m) | 5.74× |
| 2014-09-30 | $22.57M | $4.12M | $13.95M | (m) | $562.17K | $1.45M | $2.44M | (m) | 5.48× |
| 2014-06-30 | $26.49M | $3.80M | $17.87M | (m) | $803.51K | $1.11M | $2.34M | (m) | 6.98× |
| 2014-03-31 | $30.79M | $4.30M | $26.52M | (m) | $484.42K | $984.49K | $2.76M | (m) | 7.15× |
| 2013-12-31 | $31.05M | $3.66M | $26.15M | (m) | $0.00 | $1.67M | $2.71M | (m) | 8.49× |
| 2013-09-30 | $7.14M | $2.52M | $5.38M | (m) | $335.09K | $1.21M | $1.48M | (m) | 2.84× |
| 2013-06-30 | $9.17M | $2.03M | $7.65M | (m) | $236.92K | $915.16K | $1.16M | (m) | 4.52× |
| 2013-03-31 | $12.31M | $2.10M | $10.32M | (m) | $326.33K | $1.01M | $1.38M | (m) | 5.86× |
| 2012-12-31 | $13.95M | $1.82M | $12.54M | (m) | $39.11K | $1.27M | $1.06M | (m) | 7.68× |
| 2012-09-30 | $11.98M | $1.40M | $10.72M | (m) | $61.90K | $1.01M | $890.76K | (m) | 8.54× |
| 2012-06-30 | $14.62M | $1.01M | $12.89M | (m) | $220.10K | $1.20M | $790.87K | (m) | 14.54× |
| 2012-03-31 | $15.84M | $1.03M | $14.24M | (m) | (m) | $1.18M | $508.85K | (m) | 15.43× |
| 2011-12-31 | $1.29M | $2.30M | $87.77K | (m) | $0.00 | $1.15M | $1.30M | (m) | 0.56× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |